Cutera (CUTR) Downgraded by ValuEngine to “Sell”

Cutera (NASDAQ:CUTR) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, May 10th, ValuEngine reports.

A number of other brokerages also recently weighed in on CUTR. Maxim Group reissued a “hold” rating on shares of Cutera in a report on Monday, February 11th. Stephens reduced their price target on shares of Cutera from $40.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, February 21st. They noted that the move was a valuation call. TheStreet downgraded shares of Cutera from a “c” rating to a “d” rating in a report on Thursday, February 21st. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. Finally, Zacks Investment Research raised shares of Cutera from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.67.

Shares of CUTR traded up $0.21 during mid-day trading on Friday, hitting $18.18. 125,272 shares of the company’s stock were exchanged, compared to its average volume of 208,375. Cutera has a twelve month low of $12.32 and a twelve month high of $48.85. The firm has a market cap of $245.51 million, a price-to-earnings ratio of -8.15 and a beta of 0.71. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.20.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Thursday, May 9th. The medical device company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.30). The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $33.45 million. Cutera had a negative return on equity of 65.62% and a negative net margin of 22.45%. Cutera’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.02) earnings per share. As a group, research analysts predict that Cutera will post -0.66 earnings per share for the current fiscal year.

In other news, Director J Daniel Plants bought 7,145 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average price of $16.95 per share, for a total transaction of $121,107.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. PRW Wealth Management LLC increased its position in Cutera by 108.0% in the 1st quarter. PRW Wealth Management LLC now owns 1,951 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 1,013 shares in the last quarter. Financial Gravity Companies Inc. bought a new position in shares of Cutera in the 4th quarter valued at about $35,000. BNP Paribas Arbitrage SA boosted its stake in shares of Cutera by 56,660.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,838 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 2,833 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new position in shares of Cutera in the 4th quarter valued at about $65,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Cutera by 359.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 4,704 shares of the medical device company’s stock valued at $80,000 after purchasing an additional 3,680 shares during the last quarter. Hedge funds and other institutional investors own 91.50% of the company’s stock.

Cutera Company Profile

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Further Reading: Asset Allocation and Your Retirement

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.